DK1056449T3 - 20-HETE-antagonister og -agonister - Google Patents

20-HETE-antagonister og -agonister

Info

Publication number
DK1056449T3
DK1056449T3 DK99908425T DK99908425T DK1056449T3 DK 1056449 T3 DK1056449 T3 DK 1056449T3 DK 99908425 T DK99908425 T DK 99908425T DK 99908425 T DK99908425 T DK 99908425T DK 1056449 T3 DK1056449 T3 DK 1056449T3
Authority
DK
Denmark
Prior art keywords
hete
agonists
antagonists
acid
hydroxyeicosa
Prior art date
Application number
DK99908425T
Other languages
English (en)
Inventor
Richard J Roman
John R Falck
Magdalena Alonso-Galicia
Elizabeth R Jacobs
David R Harder
Original Assignee
Univ Texas
Mcw Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Mcw Res Found Inc filed Critical Univ Texas
Application granted granted Critical
Publication of DK1056449T3 publication Critical patent/DK1056449T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DK99908425T 1998-02-26 1999-02-24 20-HETE-antagonister og -agonister DK1056449T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7609198P 1998-02-26 1998-02-26
PCT/US1999/004020 WO1999043310A2 (en) 1998-02-26 1999-02-24 20-hete antagonists and agonists

Publications (1)

Publication Number Publication Date
DK1056449T3 true DK1056449T3 (da) 2003-08-11

Family

ID=22129876

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99908425T DK1056449T3 (da) 1998-02-26 1999-02-24 20-HETE-antagonister og -agonister

Country Status (13)

Country Link
US (3) US6395781B1 (da)
EP (1) EP1056449B1 (da)
JP (1) JP3921583B2 (da)
KR (1) KR100390312B1 (da)
CN (1) CN1148179C (da)
AT (1) ATE237321T1 (da)
AU (1) AU750579B2 (da)
CA (1) CA2320706C (da)
DE (1) DE69906944T2 (da)
DK (1) DK1056449T3 (da)
ES (1) ES2194444T3 (da)
PT (1) PT1056449E (da)
WO (1) WO1999043310A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
KR100767508B1 (ko) 1999-11-01 2007-10-17 다이쇼 세이야꾸 가부시끼가이샤 20-ｈｅｔｅ 생산 효소 저해제
JP2004512361A (ja) 2000-11-03 2004-04-22 エムシーダブリユー　リサーチ　フオンデーシヨン　インコーポレーテツド 脳血管疾患治療法としての２０−ｈｅｔｅ合成酵素阻害薬の使用
WO2002059072A2 (en) * 2001-01-02 2002-08-01 New York Medical College 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
EP1389611B1 (en) * 2001-04-26 2012-06-27 Taisho Pharmaceutical Co., Ltd 20-hydroxyeicosatetraenoic acid production inhibitors
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
EP1583527A1 (en) * 2002-06-14 2005-10-12 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
JP2007511522A (ja) * 2003-11-14 2007-05-10 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド 血管新生およびがん細胞増殖の調節方法
US20080306155A1 (en) * 2004-09-16 2008-12-11 Roman Richard J Method for treating renal disease
US20070004802A1 (en) * 2004-09-16 2007-01-04 Roman Richard J Method for treating renal disease
US20060063836A1 (en) * 2004-09-16 2006-03-23 Roman Richard J Method for treating renal disease
JP2009511629A (ja) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ， インコーポレイテッド 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
WO2008034011A2 (en) 2006-09-13 2008-03-20 Mcw Research Foundation, Inc. Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
US20090069418A1 (en) * 2007-04-25 2009-03-12 Alkayed Nabil J Compositions and Methods for the Treatment of Disorders Associated with Aberrant Vasodilation
EP2208720A1 (en) * 2009-01-13 2010-07-21 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Novel eicosanoid derivatives
KR102258677B1 (ko) * 2013-12-10 2021-06-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간 질환의 감별 진단
ES2738701T3 (es) 2014-01-22 2020-01-24 Max Delbrueck Centrum Fuer Molekulare Medizin Nuevos derivados de CYP-eicosanoide
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
USD1120647S1 (en) * 2024-04-16 2026-03-31 Fk Europe S.R.L. Stool

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334736A (en) 1991-05-16 1994-08-02 University Of Texas System Board Of Regents Functionalizing carbohydrate derivatives by base-induced β-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits
US5502226A (en) * 1994-11-14 1996-03-26 Elizabeth Arden Co., Division Of Conopco, Inc. Process of preparing ω-hydroxy acids
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists

Also Published As

Publication number Publication date
WO1999043310A3 (en) 1999-10-07
AU2786199A (en) 1999-09-15
ATE237321T1 (de) 2003-05-15
KR100390312B1 (ko) 2003-07-12
CN1291890A (zh) 2001-04-18
PT1056449E (pt) 2003-09-30
DE69906944D1 (de) 2003-05-22
CA2320706C (en) 2007-05-01
EP1056449A2 (en) 2000-12-06
US20020072534A1 (en) 2002-06-13
US6596769B2 (en) 2003-07-22
AU750579B2 (en) 2002-07-25
CA2320706A1 (en) 1999-09-02
KR20010034544A (ko) 2001-04-25
CN1148179C (zh) 2004-05-05
US20020049244A1 (en) 2002-04-25
DE69906944T2 (de) 2003-12-24
JP2003522098A (ja) 2003-07-22
US6605641B2 (en) 2003-08-12
US6395781B1 (en) 2002-05-28
ES2194444T3 (es) 2003-11-16
EP1056449B1 (en) 2003-04-16
JP3921583B2 (ja) 2007-05-30
WO1999043310A2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DK1056449T3 (da) 20-HETE-antagonister og -agonister
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DZ2788A1 (fr) Agonistes et antagonistes selectifs à IL-2.
NO994906D0 (no) GnRH antagonister som er modifisert i stillinger 5 og 6
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
BG105256A (en) Muscarinic agonists and antagonists
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BR9813817A (pt) Análogos de hemiasterlina
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
ATE28188T1 (de) Antikonvulsive mittel.
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
DE3674971D1 (en) P-acylaminobenzamide.
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
ITTO940212V0 (it) Attrezzatura per compassi sostitutiva dell'ago.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ATE114343T1 (de) Reinigungsvorrichtung für überhängende flächen, wie decken und rundbogen.